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Purpose: Data on the distribution and impact of panel reactive antibodies (PRA) and donor specific antibodies (DSA) before lung 
transplantation in Asia, especially multi-center-based data, are limited. This study evaluated the prevalence of and effects of PRA 
and DSA levels before lung transplantations on outcomes in Korean patients using nationwide multicenter registry data. 
Materials and Methods: This study included 103 patients who received a lung transplant at five tertiary hospitals in South Korea be-
tween March 2015 and December 2017. Mortality, primary graft dysfunction (PGD), and bronchiolitis obliterans syndrome (BOS) 
were evaluated. 
Results: Sixteen patients had class I and/or class II PRAs exceeding 50%. Ten patients (9.7%) had DSAs with a mean fluorescence 
intensity (MFI) higher than 1000, six of whom had antibodies with a high MFI (≥2000). DSAs with high MFIs were more frequent-
ly observed in patients with high-grade PGD (≥2) than in those with no or low-grade (≤1) PGD. In the 47 patients who survived 
for longer than 9 months and were evaluated for BOS after the transplant, BOS was not related to DSA or PRA levels. One-year 
mortality was more strongly related to PRA class I exceeding 50% than that under 50% (0% vs. 16.7%, p=0.007). 
Conclusion: Preoperative DSAs and PRAs are related to worse outcomes after lung transplantation. DSAs and PRAs should be 
considered when selecting lung transplant recipients, and recipients who have preoperative DSAs with high MFI values and high 
PRA levels should be monitored closely after lung transplantation.
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INTRODUCTION
Lung transplantation is an established treatment for patients 
with end-stage lung disease. The graft of an organ from a liv-
ing or deceased donor in a recipient causes many immunolog-
ical reactions, which in many cases results in failure of the al-
lograft within the recipient’s body. Whether grafts are destroyed 
by direct cytotoxicity mediated by cellular immune compo-
nents, such as T cells and NK cells, delayed-type hypersensi-
tivity reactions, or antibodies remains a critical question.1 Lung 
transplantation candidates may develop antibodies directed 
against human leukocyte antigens (HLA). Sensitization to poly-
morphic proteins, especially molecules of HLA classes I and 
II, can occur when a patient is exposed to cells from other in-
dividuals owing to pregnancy, transfusion, or transplantation. 
Immune sensitization before lung transplantation has been 
shown to be associated with increased alloreactivity and mor-
tality following transplantation.2-4
Allograft rejection is a serious complication following lung 
transplantation, leading to acute graft failure and, subsequently, 
chronic lung allograft dysfunction (CLAD).5 Bronchiolitis oblit-
erans syndrome (BOS), the most common phenotype of CLAD, 
is the leading cause of late mortality and morbidity in lung re-
cipients.5,6 Bronchiolitis obliterans is a small airway disease 
triggered by an insult to small airway epithelial and subepithe-
lial cells, with the subsequent formation of excessive fibrosis 
and airway constriction.7 Furthermore, researchers have sug-
gested that there is an immunologic link between CLAD and 
primary graft dysfunction (PGD) in the immediate post-lung 
transplant period.8 PGD of the lung is a syndrome of “acute lung 
injury” that occurs within 72 h of lung transplantation.9 PGD 
contributes to nearly half of the short-term mortality rate after 
lung transplantation.10 
In our previous study, we reported the prevalence of pre-
transplant anti-HLA antibodies and their impact on outcomes 
based on single center experience.11 However, data on the dis-
tribution and impact of panel reactive antibodies (PRA) and 
donor specific antibodies (DSA) before lung transplantation 
in Asia, especially multi-center based data, are limited, despite 
the increasing number of lung transplantations in the region. 
The Korean Organ Transplant Registry (KOTRY) was estab-
lished in 2014 as a service of the Korean Centers for Disease 
Control, and it began to register cases of lung transplantation 
in 2015.12 It is the first nationwide multi-center registry for cases 
of lung transplantation in Korea. From the multi-center regis-
try data, we sought 1) to investigate the prevalence of pre-trans-
plant PRA and DSA levels in Korean patients prior to lung 
transplantation and 2) to determine how PRA and DSA levels 
before lung transplantation affects the development of PGD, 
BOS, and mortality in Korean patients receiving a lung trans-
plant.
MATERIALS AND METHODS
Study design and population
Lung transplantation data from the KOTRY were derived from 
patients who received lung transplantation at one of five ter-
tiary teaching hospitals (Asan Medical Center, Pusan National 
University Hospital, Samsung Medical Center, Seoul National 
University Hospital, and Severance Hospital) in South Korea 
starting from March 2015. Between March 2015 and Decem-
ber 2017, 112 patients received lung transplantation. Among 
these patients, one patient who received heart-lung transplanta-
tion and eight patients who did not undergo evaluation of their 
PRA and/or DSA levels were not checked before transplanta-
tion were excluded, and finally, 103 patients were included in 
the study. The follow-up was completed in June 2018. 
Clinical settings
Transplantation was performed regardless of the status of DSA 
because of donor shortage as per a medical urgency-based al-
location system in Korea (Supplementary Table 1, only on-
line).13 Patients received induction therapy with high-dose 
steroid or IL-2 receptor antagonist, followed by standard triple 
immunosuppressive therapy consisting of the triple combina-
tion of calcineurin inhibitors, antiproliferative agents, and low-
dose steroid after lung transplantation whenever this therapy 
was not contraindicated. Pre-transplant immunological results 
did not affect the choice of immunosuppressant regimen.
Collected data and clinical outcomes
Information about the transplant recipients, donors, trans-
plant operations, and postoperative follow-up results were 
prospectively collected. Data on recipients, including general 
demographic information, primary diagnosis, and pre-trans-
plantation status, performance of desensitization protocol, 
and data on donors, including general demographic informa-
tion, cause of brain death, and smoking status, were collected. 
KOTRY also includes data on post-transplantation results, in-
cluding immediate complications, need for organ support, 
prevalence of PGD, serial pulmonary function (3, 6, 9, 12, and 
24 months after lung transplantation), and outcomes, such as 
the length of hospital stay, in-hospital and 6-month mortality, 
function status at discharge, and co-morbidities. The most re-
cent information for each patient was collected at 3, 6, 9, and 
12 months after discharge, and then annually thereafter. The 
follow-up data were collected by the attending physician and 
stored using a web-based case report form.
Furthermore, all patients included in the study underwent 
PRA class I and II identification or single antigen assays (One 
lambda, Inc., West Hills, CA, USA or Gen-Probe Inc., San Di-
ego, CA, USA) before lung transplantation. Anti-HLA antibod-
ies against donor HLA were defined as DSAs. DSAs were 
quantified based on mean fluorescence intensity (MFI), and 
the highest MFI value was recorded. The DSAs were classified 
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based on MFI as follows: MFI<1000, 1000≤MFI<2000, and 
>2000.
Clinical outcomes included PGD, BOS, and death within 1 
year after transplantation. PGD after lung transplantation rep-
resents an injury to the transplanted lung that develops in the 
first 72 h after the transplantation. The diagnosis and grading 
of PGD were based on the ratio of arterial oxygen pressure to 
the inspired oxygen concentration, as well as the presence of 
infiltration on chest radiographs, according to the Internation-
al Society for Heart and Lung Transplantation (ISHLT) crite-
ria.14 BOS was identified as a progressive decline in forced ex-
piratory volume in 1 s (FEV1) after excluding other etiologies. 
BOS was diagnosed according to the ISHLT criteria. BOS was 
defined as a >20% decrease in FEV1 from baseline. A potential 
BOS stage was defined as a 10–19% decrease in FEV1 and/or a 
≥25% decrease in FEF25–75 from baseline.15,16 The development 
of BOS was evaluated in patients who survived for longer than 
9 months. 
Statistical analysis
Descriptive statistics are reported as a number with propor-
tions or medians with min-max values. Fisher’s exact test was 
used to compare categorical variables between two groups. 
The Mann-Whitney U test was used to compare continuous 
variables between the two groups. Multivariate logistic regres-
sion models with backward variable selection were used to es-
timate the odds ratios for death within 1 year after transplan-
tation while controlling for age and sex. The Kaplan-Meier 
method was used to compare survival based on pre-transplant 
calculated panel-reactive antibody (cPRAs) and DSAs. All sta-
tistical analyses were performed using SPSS version 25.0 (IBM 
Corp., Armonk, NY, USA). A p value of <0.05 was considered 
statistically significant.
Ethics statement
Written informed consent is obtained from each patient prior 
to transplantation. If patients are unable to provide consent 
due to disease severity, informed consent is obtained from a 
relative or legal representative. This KOTRY study was reviewed 
and approved by the Institutional Ethics Committees of each 
participating organization including the Institutional Review 
Board of Severance Hospital (IRB no. 4-2018-1187).
RESULTS
Baseline characteristics
The baseline characteristics of the recipients according to the 




No (n=93) Yes (n=10)
Age (yr) 58 (25–73) 58 (25–73) 55 (44–62) 0.262
Male 65 (63.1) 63 (67.7) 2 (20) 0.005
BMI (kg/m2) 21.2 (12.3–29.0) 21.3 (12.3–29.0) 19.8 (14.4–24.8) 0.612
ABO blood type 0.017
A 41 (39.8) 38 (40.9) 3 (30)
B 25 (24.3) 25 (26.9) 0 (0)
AB 12 (11.7) 8 (8.6) 4 (40)
O 25 (24.3) 22 (23.7) 3 (30)
Primary diagnosis 0.220
COPD 4 (3.9) 4 (4.3) 0 (0)
Idiopathic pulmonary fibrosis 56 (54.4) 53 (57.0) 3 (30)
Idiopathic pulmonary artery hypertension 1 (1.0) 1 (1.1) 0 (0)
Bronchiectasis 3 (2.9) 2 (2.2) 1 (10)
Bronchiolitis obliterans syndrome after HSCT 10 (9.7) 10 (10.8) 0 (0)
Connective tissue disease related ILD 17 (16.5) 14 (15.1) 3 (30)
Lymphangioleiomyomatosis 2 (1.9) 2 (2.2) 0 (0)
Others* 10 (9.7) 7 (7.5) 3 (30)
Smoking 0.317
Ever smoker 50 (48.5) 47 (50.5) 3 (30)
 <20 pack-years 15 (14.6) 13 (14.0) 2 (20)
≥20 pack-years 35 (34.9) 34 (36.5) 1 (10)
Never smoker 53 (51.5) 46 (49.5) 7 (70)
Bilateral lung transplantation 99 (96.1) 90 (96.8) 9 (90) 0.340
BMI, body mass index; COPD, chronic obstructive pulmonary disease; HSCT, hematopoietic stem cell transplantation; ILD, interstitial lung disease.
Values are presented as the median (min-max) or number of patients (%).
*Acute respiratory distress syndrome, eisenmenger syndrome.
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presence of DSAs are shown in Table 1. Ten patients (9.7%) 
had DSAs before lung transplantation. The median patient age 
was 58 years (min 25, max 78 years), and 65 recipients (63.1%) 
were male. The primary diagnosis was idiopathic pulmonary fi-
brosis in 56 cases (54.4%), chronic obstructive pulmonary dis-
ease in four cases (3.9%), idiopathic pulmonary artery hyper-
tension in one case (1.0%), bronchiectasis in three cases (2.9%), 
BOS after stem cell transplantation in 10 cases (9.7%), intersti-
tial lung disease with connective tissue disease in 17 cases 
(16.5%), lymphangioleiomyomatosis in two cases (1.9%), and 
other diseases in 10 cases (9.7%). The proportion of patients who 
were male or had ABO blood type B was higher in the group of 
patients who did not have DSAs than in the group of patients 
with DSAs.
The prevalence of cPRAs and DSAs are shown in Table 2. 
Among the patients, high levels of class I or II cPRAs (≥50%) 
were detected in 16 patients (15.5%), low levels of class I and/
or II cPRAs (<50%) were detected in 40 patients (38.9%), and 
cPRAs were not detected in 47 patients (45.6%). In terms of 
the distribution of MFIs of DSAs, four patients (3.9%) had anti-
HLA antibodies with MFI of 1000–2000, and six (5.8%) had an 
MFI higher than 2000. 
The characteristics of 10 patients who had DSAs are shown 
in Table 3. Among the 10 patients, four patients underwent a 
desensitization process before lung transplantation. Of these 
four patients, three died within 1 year after the lung transplan-
tation, and the remaining one patient had grade 3 BOS (pa-
tient number 1). Among the six patients who did not undergo 
desensitization, three patients (patient number 5, 8, and 9) had 
MFIs higher than 2000, of whom two patients (patient num-
ber 5 and 9) survived for over 1 year and did not develop high-
grade BOS. Among the four patients (patient number 3, 6, 8, and 
10) who died within 1 year, two patients (patient number 3 and 
8) died of respiratory failure.
Outcomes
As shown in Table 4, patients were divided into two groups 
based on PGD grade: grade 0–1, non-high-grade PGD group, 
and grade ≥2, high-grade PGD. Twenty-two patients (21.4%) 
developed high-grade PGD. Furthermore, high-grade PGD 
developed more frequently in patients with DSAs that had MFI 
values higher than 2000 than in patients with DSAs that had 
MFI values lower than 2000 (p=0.029). A high cPRAs (≥50%) 
Table 2. Prevalence of Pre-Transplant Panel-Reactive and Donor-Specif-
ic Antibodies
Variable Total Class I* Class II†
Calculated panel-reactive antibody
Not detected 47 (45.6) 62 (60.2) 70 (68.0)
PRA <50% 40 (38.9) 34 (33.0) 24 (23.3)
PRA ≥50% 16 (15.5) 7 (6.8) 9 (8.7)
Donor-specific antibody MFI
<1000 93 (90.3) 98 (95.1) 97 (94.2)
1000–2000 4 (3.9) 2 (1.9) 2 (1.9)
≥2000 6 (5.8) 3 (2.9) 4 (3.9)
PRA, panel reactive antibodies; MFI, mean fluorescence intensity.
Values are presented as the number of patients (%).
*HLA-A, HLA-B, and HLA-C, †HLA-DQ and HLA-DR.












1 year after lung 
transplantation





100 Yes 1 BOS grade 3 No -





    6 Yes 2 N/A* Yes Asphyxia








  75 Yes 0 N/A* Yes Unknown
7 Female/56 DR52 (1160)      0 No 0 No No -
8 Male/61 B44 (5026)   61 No 2 N/A* Yes Respiratory failure




  56 Yes 0 N/A* Yes Unknown
MFI, mean fluorescence intensity; cPRA, calculated panel-reactive antibody; PGD, primary graft dysfunction; BOS, bronchiolitis obliterans syndrome; N/A, not 
applicable.
*Could not perform pulmonary function test sufficiently to evaluate BOS, †Was not followed-up up to 1 year.
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was not associated with the development of high-grade PGD 
for both class I and II antibodies.
As shown in Table 5, patients were divided into two groups 
based on BOS grade: grade 0–0p, non-BOS; and grade ≥1, BOS. 
Forty-seven patients who survived longer than 9 months after 
the lung transplantation and underwent regular pulmonary 
function tests were evaluated. Among the 47 patients, the me-
dian follow-up time was 27.5 months (min 5.6 months and max 
38.6 months), and BOS developed in 10 patients (21.3%). BOS 
development was not related to cPRA or the MFI of DSAs for 
both class I and II antibodies. 
There was no significant difference in survival rates when 
stratified by pre-transplant cPRAs and DSAs according to anal-
ysis of Kaplan-Meier survival curves (Fig. 1). The association 
between pre-transplant anti-HLA antibodies and death with-
in 1 year after transplantation is shown in Table 6. Among the 
103 patients, data regarding death within 1 year after trans-
plantation were available for 78 patients. In total, high cPRA 
levels (p=0.050) and MFIs of DSAs (p=0.719) were not related 
to death within 1 year after transplantation. However, when 
considering only class I anti-HLA antibodies, high cPRA levels 
(p=0.007) were related to death within 1 year after transplan-
tation, and although not statistically significant, death within 
1 year after transplantation was more frequent in patients who 
had MFIs of DSAs higher than 2000 (p=0.053). Supplementary 
Table 2 (only online) shows the results of the multivariate lo-
gistic regression analysis for factors contributing to death 
within 1 year after transplantation. When age and sex were in-
cluded in the regression model, high cPRA levels in class I 
(odds ratio: 3.558, 95% confidence interval: 0.941–13.446, p= 
0.061) tend to be related with death within 1 year after trans-
plantation, although statistical significance was not observed.
DISCUSSION 
The major strength of this study was that it was a nationwide 
study using thoroughly collected data, enhancing our ability 
to generalize the study results. The KOTRY allowed investiga-
tion of the prevalence of PRA and DSA levels in Korean lung 
transplantation patients prior to lung transplant and how PRA 
Table 4. Association of Pre-Transplant Panel-Reactive and Donor-Specif-








Not detected or cPRA <50% 69 (85.2) 18 (81.8)
cPRA ≥50% 12 (14.8) 4 (18.2)
Donor-specific antibody MFI 0.029
<1000 75 (92.6) 18 (81.8)
1000–2000 4 (4.9) 0 (0)
≥2000 2 (2.5) 4 (18.2)
Class I
cPRA >0.999
Not detected or cPRA <50% 75 (92.6) 21(95.5)
cPRA ≥50% 6 (7.4) 1 (4.5)
Donor-specific antibody MFI 0.154
<1000 78 (96.3) 20 (90.9)
1000–2000 2 (2.5) 0 (0)
≥2000 1 (1.2) 2 (9.1)
Class II
cPRA 0.398
Not detected or cPRA <50% 75 (92.6) 19 (86.4)
cPRA ≥50% 6 (7.4)  3 (13.6)
Donor-specific antibody MFI 0.036
<1000 78 (96.3) 19 (86.4)
1000–2000 2 (2.5) 0 (0)
≥2000 1 (1.2) 3 (13.6)
cPRA, calculated panel-reactive antibody; MFI, mean fluorescence intensity.
Values are presented as the number of patients (%).
Table 5. Associations of Pre-Transplant Panel Reactive and Donor-








Not detected or cPRA <50% 34 (91.9) 9 (90)
cPRA ≥50% 3 (8.1) 1 (10)
Donor-specific antibody MFI 0.285
<1000 34 (91.9) 8 (80)
1000–2000 1 (2.7) 1 (10)
≥2000 2 (5.4) 1 (10)
Class I
cPRA N/A
Not detected or cPRA <50% 37 (100) 10 (100)
cPRA ≥50% 0 (0) 0 (0)
Donor-specific antibody MFI 0.213
<1000 37 (100) 9 (90)
1000–2000 0 (0) 1 (10)
≥2000 0 (0) 0 (0)
Class II
cPRA >0.999
Not detected or cPRA <50% 34 (91.9) 9 (90)
cPRA ≥50% 3 (8.1) 1 (10)
Donor-specific antibody MFI 0.630
<1000 34 (91.9) 9 (90)
1000–2000 1 (2.7) 0 (0)
≥2000 2 (5.4) 1 (10)
BOS, bronchiolitis obliterans syndrome; cPRA, calculated panel-reactive anti-
body; MFI, mean fluorescence intensity; N/A, not applicable.
Forty-seven patients survived for longer than 9 months after lung transplan-
tation and underwent pulmonary function test for chronic lung allograft dys-
function.
Values are presented as the number of patients (%).
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and DSA levels before lung transplantation are related to pa-
tient outcomes. A high level of DSAs was related to high-grade 
PGD, and class I cPRA levels exceeding 50% were related to a 
higher number of deaths within 1 year after transplantation. 
In this nationwide registry, the prevalences of high cPRA 
(≥50%) (class I, 6.8%; class II, 8.7%; total, 15.5%) and DSA (MFI 
≥1000) (class I, 4.8%; class II 5.8%; total 9.7%) levels were com-
parable to data for Western countries. In a study performed in 
Belgium, 17% of the patients had MFIs for DSAs higher than 
500, as detected by the Luminex assay.17 In a study performed 
in France, 89% of the patients had either anti-HLA class I or II 
antibodies, and 32% had DSA (MFIs higher than 300), as de-
tected by the Luminex assay.18 Additionally, in a single center 
study performed in the United States, 8.9% of the patients had 
DSA with MFIs greater than 1000, as detected by the Luminex 
assay. There were inconsistencies between the data from Bel-
gium and France and data from the United States and this 
study; however, these inconsistencies may be attributable to dif-
ferences in MFI cutoffs. The proportion of patients with a high 
cPRA (>50%) (class I, 7.9%; class II, 5.3%; total, 11.8%) in our 
previous single-center study was similar to that in a multi-cen-
ter study.11 
Although a relationship between PGD and DSAs has been 
previously shown and studies have investigated the associa-
tion between BOS and anti-HLA antibodies, the relationship 
between BOS and anti-HLA antibodies is unclear.19-21 BOS and 
anti-HLA antibodies were not found to be related in this study 
probably because we were only able to analyze the presence 
of BOS in only 47 patients, and among them, only 10 had BOS. 
Further, the follow-up duration was relatively short. A more ac-
curate assessment would be possible if further data of trans-
plant patients are accumulated. Furthermore, PGD has multi-
factorial causes, and based on previous studies, as well as the 
results of this study, an immunological response may be one 
of the mechanisms of PGD.22 Furthermore, PGD is considered 
a risk factor for CLAD23; therefore, PGD being related to anti-
HLA antibodies could imply an immunological link between 
CLAD and PGD in the immediate post-lung transplantation 
period.8 
The cut-off values for cPRA and DSA MFI in lung transplan-
tation patients differ among studies.18-22 This study used cut-
off values of 50% for cPRAs and 1000 and 2000 for DSA MFI. 
The Stanford pre-lung transplant HLA antibody management 
protocol recommends intervention if cPRA values are higher 
than 50%.24 Some labs define DSA MFI >1000 as DSA-posi-
tive, while some consider DSA MFI >2000 to be clinically sig-
nificant DSA-positive.25 Further studies including prospective 
studies are needed to clarify the cut-off point for lung trans-
Table 6. Associations for Pre-Transplant Panel-Reactive and Donor-










Not detected or cPRA <50% 44 (91.7) 22 (73.3)
cPRA ≥50% 4 (8.3) 8 (26.7)
Donor-specific antibody MFI 0.719
<1000 44 (91.7) 26 (86.7)
1000–2000 2 (4.2) 1 (3.3)
≥2000 2 (4.2) 3 (10)
Class I
cPRA 0.007
Not detected or cPRA <50% 48 (100) 25 (83.3)
cPRA ≥50% 0 (0) 5 (16.7)
Donor-specific antibody MFI 0.053
<1000 47 (97.9) 26 (86.7)
1000–2000 1 (2.1) 1 (3.3)
≥2000 0 (0) 3 (10)
Class II
cPRA >0.999
Not detected or cPRA <50% 44 (91.7) 27 (90)
cPRA ≥50% 4 (8.3) 3 (10)
Donor-specific antibody MFI >0.999
<1000 45 (93.8) 29 (96.7)
1000–2000 1 (2.1) 0 (0)
≥2000 2 (4.2) 1 (3.3)
cPRA, calculated panel-reactive antibody; MFI, mean fluorescence intensity.













0                         10                        20                        30                        40
0                         10                        20                        30                        40
  Not detected or cPRA <50%
   cPRA ≥50% 
p=0.081
Donor specific antibody MFI
  <1000
   ≥1000 
p=0.690
Months of follow up after lung transplantation











Fig. 1. Kaplan-Meier survival curves stratified by pre-transplant panel-re-
active antibodies (A) and donor-specific antibodies (B). cPRA, calculated 
panel-reactive antibody; MFI, mean fluorescence intensity.
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plantation patients.
This study showed differences in 1-year mortality between 
patients with HLA class I and II antibodies. There is growing 
evidence that class I and II antibodies are associated with clini-
cally different outcomes.26 In patients undergoing renal trans-
plantation, the presence and level of class II DSAs and its level 
at the time of transplantation are associated with worse out-
comes, while that of class I DSA is not.27 However, we cannot 
confirm if our results were different because a different organ 
was studied or because of other reasons; therefore, further stud-
ies in this regard are needed. 
In this study, desensitization was performed in only four out 
of 10 patients with DSA of moderate to high MFIs; however, 
the prognosis of patients who underwent desensitization was 
poor. Desensitization for each patient was based on the clinical 
practice of the individual center rather than the trial protocol. 
The Toronto Lung Transplant Program developed a protocol 
for the management of sensitized transplant candidates guid-
ing organ allocation, perioperative desensitization, and main-
tenance immunotherapy.28 However, evidence on the efficacy 
of desensitization in patients undergoing lung transplantation 
are insufficient.17,29 In the study by Snyder, et al.,30 an aggressive 
multi-modal desensitization protocol that included plasma-
pheresis, steroids, bortezomib, and rituximab did not signifi-
cantly reduce the levels of pre-transplant HLA antibodies. Fur-
ther studies are required to examine the efficacy and indication 
of desensitization in patients with high levels of cPRAs or DSAs 
before lung transplantation.
As mentioned earlier, sensitization to HLA class I and II mol-
ecules can occur when a patient is exposed to cells from oth-
er individuals due to pregnancy, transfusion, or transplanta-
tion.29,31,32 This may explain why the prevalence of DSAs was 
higher in female patients.33 Furthermore, sensitizing events, 
such as blood transfusions, which result in the accumulation of 
pre-transplant antibodies, should be avoided as much as clini-
cally feasible. The majority of patients receive at least three 
units of red blood cells in the perioperative period.34 Blood 
transfusion before lung transplantation is known to be a nega-
tive predictive factor and is associated with transfusion-relat-
ed acute lung injury and transfusion-associated circulatory 
overload, pneumonia, and Epstein-Barr virus infection.34,35
Our study had some limitations. First, this was a relatively 
small retrospective study with a short follow-up period. Thus, 
adjustment for many prognostic factors that could affect sur-
vival among lung transplantation patients could not be per-
formed in this study. However, this was the first multi-institu-
tional attempt to evaluate the impact of anti-HLA antibodies 
in Korean patients using nationwide lung transplantation co-
hort data. Second, post-transplant DSAs were not routinely 
checked or included in the analysis. Moreover, restrictive al-
lograft syndrome, a form of CLAD other than BOS, was sur-
veyed but could not be included in this study because only two 
patients showed a restrictive allograft syndrome phenotype. 
Third, donor lungs are allocated to the most urgent cases based 
on the Korean Network for Organ Sharing urgency status in-
stead of the lung allocation score system, which is the most 
widely used allocation system in the world. 
In conclusion, KOTRY data were used to demonstrate how 
PRA and DSA levels before lung transplantation are related to 
outcomes in the Korean population. High levels of DSAs were 
related to high-grade PGD, and a PRA class I level exceeding 
50% was related to 1-year mortality. DSA and PRA levels should 
be considered in selecting lung transplantation recipients, and 
recipients who have high preoperative DSA MFIs and PRA 
should be monitored closely after lung transplantation.
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